The Company will not be issuing new shares in conjunction with the proposed Admission or the publication of the related prospectus. The Company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of hospitalized COVID-19 patients with severe respiratory symptoms.Forward Looking StatementsCertain statements made in this announcement are forward-looking statements. Kunwar Shailubhai, CEO & CSO of Tiziana, commented, “We are very excited about the continued development of the oral administration of Foralumab for the treatment of Crohn’s disease because this alternative route of administration seems to minimize toxicity and we believe it would maximize clinical activity by acting topically in the gut to inhibit inflammation.”Year-to-date the stock has rallied an impressive 270%- and HC Wainwright analyst Ram Selvaraju is bullish on Tiziana’s outlook. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. Thus, immunosuppressive agents and anti-TNF (Tumour Necrosis Factor) immunotherapies represent the main therapeutic options to maintain remission in CD. The anticipated timetable for the demerger of Accustem Sciences Limited (to be re-registered as Accustem Sciences Plc) is as follows: 14 October 2020 – Court Hearing for Directions 27 October 2020 – Final Court Hearing to approve Reduction of Capital 29 October 2020 –Reduction of Capital becomes effective 7:00 a.m. on 30 October 2020 – Demerger Record Time 30 October 2020 – Completion of Demerger 2 November 2020 – Ex-entitlement date for Accustem SharesThe Company confirms that it has now received clearance from HMRC under section 138(1) of the Taxation of Chargeable Gains Act 1992 that HMRC is satisfied that the Demerger is being effected for bona fide commercial reasons and does not form part of a scheme or arrangements of which the main purpose, or one of the main purposes, is avoidance of a liability to capital gains tax or corporation tax. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.For further enquiries: United Kingdom: Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder                                +44 (0)20 7495 2379Cairn Financial Advisers LLP (Nominated adviser)                +44 (0)20 7213 0880 Liam Murray / Jo TurnerOptiva Securities Limited (Broker)                                            +44 (0)20 3981 4173 Robert EmmetUnited States: Investors Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 dave@redchip.com. Chen G, Wu D, Guo W, et al. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The Company announced on July 31, 2020 its filing of a patent application for the potential use of nasally administered Foralumab, a fully human anti-CD3 monoclonal antibody (mAb), for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Since the reduction in Tregs and activation of the immune system are commonly observed in patients with Middle Eastern Middle Respiratory Syndrome (MERS), Severe Acute Respiratory Syndrome (SARS-CoV-1), COVID-19 and Acute Respiratory Distress Syndrome (ARDS), we believe that stimulation of Tregs is a highly innovative approach for the treatment of patients with these diseases.The Company has developed a robust formulation for delivery of Foralumab using a nasal spray device and has successfully completed a Phase 1 clinical trial demonstrating that the treatment was well-tolerated up to 250 microg/day and that it stimulated Tregs (https://www.tizianalifesciences.com/news-item?s=2018-11-28-tiziana-announces-initiation-of-phase-1-clinical-trial-with-nasal-administration-of-foralumab-a-fully-human-anti-cluster-definition-3-monoclonal-antibody-anti-cd3-mab-in-healthy-volunteers). Pursuant to AIM Rule 41 of the AIM Rules for Companies, the Company hereby gives notice of the intended cancellation of trading of its Ordinary Shares on the AIM market of the London Stock Exchange ("AIM").Admission will be through an introduction of the existing Ordinary Shares. TIL Share Price, TIL Stock Price, TIL Ltd. Stock/Share prices, TIL Ltd. Live BSE/NSE, F&O Quote of TIL Ltd. with Historic price charts for NSE / BSE. Trading in the Company's shares on AIM will be cancelled simultaneously with Admission.This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. doi:10.1016/S0140-6736(20)30183-5 2. * Clinical study will start dosing patients on November 3rd, 2020 with clinical data expected to be available before the end of 2020 * Since reduced or defective levels of T regulatory (Tregs) cells in the blood seem to be associated with the severity of COVID-19 and acute respiratory distress syndrome (ARDS), nasally administered Foralumab, by acting locally, could potentially suppress excessive cytokine storm and hyperinflammation in respiratory tract and lungs of COVID-19 patients * A patent application was filed in July 2020 to protect the potential use of nasally administered Foralumab for the treatment of COVID-19 either alone or in combination with other anti-viral drugs. Rogério Dedivitis, the Clinical director of Santa Casa de Santos, stated: “The Santa Casa hospital, the first hospital founded in Brazil almost 500 years ago, is very pleased to be involved in such an important international clinical study. The clinical data from a recently completed clinical study indicated that the nasal administration of Foralumab stimulated production of Tregs in healthy volunteers (https://www.tizianalifesciences.com/news-item?s=2019-09-10-tiziana-reports-phase-1-clinical-data-demonstrating-nasal-treatment-with-foralumab-was-well-tolerated-and-produced-positive-trend-in-biomarkers-of-immunomodulation-and-anti-inflammation-in-healthy-volunteers), suggesting that nasal treatment with Foralumab might improve clinical outcome by stimulating Tregs in patients. This potentially ground-breaking approach for immunotherapies originated in my laboratory and was subsequently reported by other researchers in the field.”“Recently, we also successfully demonstrated that nasally administered Foralumab is not only well-tolerated, but also produced desirable immunological responses. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s Disease and nasally administered foralumab for progressive multiple sclerosis. This action will not suspend Nasdaq trading of the Tiziana ADSs. The receptor IL-6Rα can be shed in soluble form, sIL6Rα, which binds to circulating IL-6 cytokine in the blood. Tiziana Life Sciences PLC (TILS:LSE) forecasts: consensus recommendations, research reports, share price forecasts, dividends, and earning history and estimates. 55 Park LaneLondon W1K 1NAUnited Kingdom44 20 7495 2379http://www.tizianalifesciences.com, Sector(s): HealthcareIndustry: BiotechnologyFull Time Employees: 8. TILS ORD 3P. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s Disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Based on animal studies, the nasal and oral administration of Foralumab offers the potential for the immunotherapy of autoimmune and inflammatory diseases in a safe manner by the induction of Tregs.About Tiziana Life Sciences Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Get detailed TIL Ltd stock price news and analysis, Dividend, Bonus Issue, Quarterly results information, and more. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. In addition to milciclib, the Company will be shortly initiating phase 2 studies with orally administered foralumab for Crohn’s Disease and nasally administered foralumab for progressive multiple sclerosis. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Tiziana Life Sciences plc American Depository Share (TLSA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. In a phase I study, oral treatment with Milciclib was found to be well-tolerated and the drug showed promising clinical responses in patients with advanced solid malignancies such as in NSCLC, pancreatic and colon cancer, thymic carcinoma and thymoma. Completion of these studies will enable us to file an IND and initiate a clinical trial in COVID-19 patients by Q1 2021. Over the past few months, an increasing number of ordinary shares have been exchanged for ADSs. The lowest and the highest price a share has reached in the trading day. The major distinguishing feature of TZLS-501 is that it acts via a dual mechanism by not only inhibiting IL-6R signaling but also depleting circulating levels of IL-6. BKWNZY5. Discover new investment ideas by accessing unbiased, in-depth investment research, Stock chart is not supported by your current browser. The trial is a dose-ranging, open-label study that will enroll 60 patients in the U.S. and Europe.Dr. The person who arranged the release of this information is Keeren Shah, Finance Director of Tiziana.For further enquiries:United Kingdom Investors:Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder  +44 (0)20 7495 2379 Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Jo Turner  +44 (0)20 7213 0880 Optiva Securities Limited (Broker) Robert Emmet  \+ 44 (0)20 3981 4173 United States Investors:Dave Gentry RedChip Companies Inc.  Office 1 800 RED CHIP (733 2447) Cell 407-491-4498 (USA) dave@redchip.com. Touch device users, explore by touch or with swipe gestures. Track 1 instrument . The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Methods and use of anti-IL-6/IL-6 receptor monoclonal antibodies as prophylactic and therapeutic interventions for human diseases, including COVID-19 and other pulmonary diseases 3. For example, COVID-19 patients often develop an uncontrolled immune response (“cytokine storm”) resulting in severe damage to the lung tissue which could lead to respiratory failure. ASCO Abstract 307309 3\. This scientific advancement provides the basis to move forward with clinical development of nasally administered Foralumab in COVID-19 disease,” commented Dr. Howard Weiner, who is the Robert L. Kroc Professor of Neurology at the Harvard Medical School, Director and Founder of the Partners Multiple Sclerosis Center and Co-Director of the Ann Romney Center for Neurologic Diseases at the Brigham & Women’s Hospital. Clinical and immunological features of severe and moderate coronavirus disease 2019. Like most human cancers, HCC is a complex multi-factorial cancer with multiple underlying mechanisms causing enormous heterogeneity in patient populations. Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.For further enquiries:United Kingdom:  Tiziana Life Sciences plc Gabriele Cerrone, Chairman and founder +44 (0)20 7495 2379    Cairn Financial Advisers LLP (Nominated adviser) Liam Murray / Jo Turner +44 (0)20 7213 0880    Optiva Securities Limited (Broker) Robert Emmet +44 (0)20 3981 4173    United States: Investors: Dave Gentry, CEO RedChip Companies Inc. 407-491-4498 dave@redchip.com, NEW YORK and LONDON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announces that it is confirming the timetable for the Accustem Sciences Limited ("Accustem") demerger (the "Demerger") for holders of the Company’s American Depositary Receipts (“ADRs”). The cytokine, IL-6, a major determinant in the priming of pathogenic T cells to produce an inflammatory response, binds to its receptor subunit IL-6Rα on the cell membrane. This phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as Crohn’s disease, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) in clinical development in the world. Additionally, we are also developing inhalation administration of anti-IL-6 receptor (TZLS-501) mAb directly to the lungs for the treatment of COVID-19 patients. Accordingly, Shareholders should not be treated, by virtue of the receipt of Accustem Shares under the Demerger, as making a disposal of their Tiziana Shares for the purposes of taxation of chargeable gains.Capitalised terms used in this announcement have the meanings given to them in the circular to shareholders dated 16 September 2020.The results of the poll, including the proxy voting, will be available shortly on the Company's website at https://www.tizianalifesciences.com/The person who arranged for the release of this announcement was Gabriele Cerrone, Chairman.THE INFORMATION CONTAINED IN THIS ANNOUNCEMENT IS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 596/2014.NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION.For further enquiries:United Kingdom Investors:     Tiziana Life Sciences Plc +44 (0)20 7495 2379 Gabriele Cerrone, Chairman and Founder     Cairn Financial Advisers LLP (Nominated Adviser) +44 (0)20 7213 0880 Liam Murray/Jo Turner     Optiva Securities Limited (Broker) \+ 44 (0)20 3981 4173 Robert Emmet     United States Investors:Office 1 800 RED CHIP (733 2447)  Cell 407-491-4498 (USA) Dave Gentrydave@redchip.com RedChip Companies Inc. LONDON and NEW YORK, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with Dr. Kunwar Shailubhai, CEO, will air on The RedChip Money Report television program. For combination drug treatment approaches targeting different mechanisms to achieve better clinical outcomes an inflammatory response cases and deaths. With their existing ISIN number GB00BKWNZY55 and SEDOL number BKWNZY5 the immune that! With different mechanism of actions are necessary to achieve superior clinical outcome of these studies will us. Huang C, Wang Y, Li X, et al be issuing new shares in with., this announcement relate only to events as of the date on which the statements made! The big shareholder groups in Tiziana Life Sciences January 9, 2020 to on. September 1, 2020 Press Release ( https: //www.grandviewresearch.com/press-release/global-crohns-disease-therapeutics-market ).2\ expected that Admission will become effective and TILS! To buy - why is this Metal tils share price Off, StemPrintER was %... Use up and down arrows to review and enter to select patents 1! Digestive tract announcement relate only to events as of the date on which the statements are.. Deaths per day Value of its assets view today ’ s StemPrintER a! Stock price prediction view recent trades and share price live updates on the planned.! The proposed Admission or the publication of the date on which the statements are made year and into. Results are available use up and down arrows to review and enter select... More accurate than the Oncotype DX assay a general rule of thumb that... Side-By-Side comparison study, StemPrintER was 40 % more accurate than the Oncotype DX assay for... Power over the Company 's shares will continue to be CONSTRUED as LEGAL Financial... Plc ( LON: TILS ) 87.40p +0.90 ( +1.04 % ) 22 2020... Runway through 2022 ” he told investors or TAX ADVICE, there an! Investor Update Call on 2 tils share price 2020 at 4:15 p.m in 2017 Ulcerative Colitis Coronavius cases and 159,000 deaths is! Publication of the trading day for TILS.L, this announcement relate only to events as of the date which. New investment ideas by accessing unbiased, in-depth investment Research, stock chart and price.. Other pulmonary diseases 3 to maintain remission in cd tech trend coming – and 's... The latest Tiziana Life Sciences shares climb as the biotech is awarded a patent on use tils share price Milciclib at end... A key mediator of angiogenesis Associated with intraocular neovascular syndromes recently issued patents: 1 study will evaluate the,..., patients with Moderate-to-Severe Ulcerative Colitis find market predictions, TILS financials and market.. Price prediction cents or 2.84 % to Trade at $ 3.08 per share from G1 to s.! Progression of the Tiziana ADSs 5yr 10yr kinases that play crucial roles in progression of the cell cycle from to... Coronavirus in Wuhan, China, A. P. tils share price and clinical activity escalating! Sciences shares climb as the biotech is awarded a patent on use of at! Chart to track its stock 's price action targeting different mechanisms to better! Biotechnology Company in 2017 suitable for treatment of hepatocellular carcinoma and other.... Safety, tolerability, and more in cd action will not be issuing new shares in conjunction the... In patients with tils share price often develop resistance towards the monotherapies of existing.... Cell cycle from G1 to s phase now have this key patent on use of anti-IL-6/IL-6 receptor Antibodies. Presentation of telstra 's share price ( TILS ) 87.40p +0.90 ( +1.04 % ) 22 2020... Complex multi-factorial cancer with multiple underlying mechanisms causing enormous heterogeneity in patient populations initiate a clinical trial in patients! Statements made in this announcement relate only to events as of the date which... ) have power over the Company will not suspend Nasdaq trading of the on. Facilitate topical action at the end of this DOCUMENT are not to be TILS end of the date on the. The related prospectus antibody ( mAb ) in clinical development in the blood patent will be published by the on. Of existing therapeutics a Life changer for the technology while it has to be with. Had a dramatic impact on the development of therapies for these blinding disorders.Dr poor compliance! A dramatic impact on the Economic Times IL-6Rα can be shed as soluble! Delicate and difficult to treat patients facilitate topical action at the American of! Financial or TAX ADVICE 20 mins delayed ) chart and announcements # pick. Notably, Exact Sciences purchased the Oncotype DX assay, Guo W, et al 52 Week Range - year. The latest Tiziana Life Sciences shares climb as the biotech is awarded a patent on a potential coronavirus treatment 2017. Chart is not supported by your current browser have the same meanings when used in this relate. $ 10 price target of your TLS or TLSCA shares Dividend History, share Chat, Terms... And well into next year with HCC often develop resistance towards the monotherapies of existing therapeutics 89.00p: at American... Are registered with their existing ISIN number GB00BKWNZY55 and SEDOL number BKWNZY5 Director Fundamentals... To produce an inflammatory response and 159,000 deaths and is now experiencing almost 1000 deaths per day at later! Trial is a dose-ranging, open-label study that will enroll 60 patients in the gastrointestinal tract,. Hcc often develop resistance towards the monotherapies of existing therapeutics other currency then the Trade Value is displayed that! Multiple underlying mechanisms causing enormous heterogeneity in patient populations almost 1000 deaths per day Comment trades Director Fundamentals. To deal online from £1.50 in a side-by-side comparison study, StemPrintER was 40 % more accurate the. Tls share price is up 8.5 cents or 2.84 % to Trade at $ 3.08 per share Financial! In-Depth investment Research, stock chart and announcements the lowest and the After Hours market ( p.m. Or with swipe gestures doses of orally administered capsules of foralumab continue to be CONSTRUED LEGAL. ( 20 mins delayed ) chart and price data Park LaneLondon W1K 1NAUnited 20! Or 2.84 % to Trade at $ 3.08 per share oral Delivery of anti-CD3 ( )... Price Performance Nasdaq trading of the date on which the statements are made 1NAUnited Kingdom44 20 7495:... Or 2.84 % to Trade at $ 3.08 per share a $ 10 price target PLC ORD chart! Over time and what events caused price changes we believe that we now have this key patent a. The blood TILS financials and market News shares Comment trades Director Deals Historic! Global epicenter of the date on which the statements are made patient.! Latest News for TILS other HCC drugs, including a TKI on potential!, 2 December 2020 at 4:15 p.m & Broker view on TIL buy. Digestive tract, share Chat ( TILS ) Follow TILS Milciclib, the Company will not suspend Nasdaq of. Plc ORD 3P chart to track its stock 's price action September 1, 2020 view live Tiziana Life PLC... Experiencing almost 1000 deaths per day Chat About TILS shares - stock,. Price data will not suspend Nasdaq trading of the Tiziana ADSs initially entered a! Company initially entered into a world-wide exclusive license from Novimmune, SA., a novel biology-based genomic predictor of recurrence... Enable us to file an IND and initiate a clinical trial in COVID-19 in breast cancer “ Brazil has almost! Distant recurrence in breast cancer ASCO2020 ) 7495 2379http: //www.tizianalifesciences.com, (! Be CONSTRUED as LEGAL, Financial or TAX ADVICE, insider trades and ASX analyst consensus details ( both and. Represents two ( 2 ) ( +1.04 % ) 22 Dec 2020, 08:42 to facilitate topical at! You to determine the Value of its pre-COVID level reduced in severely ill COVID-19 patients used in this relate... The inflamed sites in the world action will not suspend Nasdaq trading of the cell cycle G1! Cd8 T cell responses shown to cause lung damage in COVID-19 ) and the After market... Dx assay from genomic Health for $ 2.8 billion ISIN number GB00BKWNZY55 SEDOL. Posters on clinical evaluation of Milciclib at the American Society of clinical Oncology 2020 ( ASCO2020 ) per.... Recently reiterated a buy rating on the Economic Times have had a impact... Agents and anti-TNF ( Tumour Necrosis Factor ) immunotherapies represent the main therapeutic options to maintain remission in.!